Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) is a blank-check special purpose acquisition company formed to identify and complete a business combination in the biomedical and life sciences sector. EUCR completed its initial public offering in 2021 and, as reflected in its Form 10-Q filed November 22, 2021, was at that time in the pre-combination search phase, screening acquisition targets across the healthcare and biopharmaceutical landscape. The quarterly filing covers standard operational and financial disclosures consistent with a SPAC that has not yet announced a definitive merger agreement. Investors and researchers seeking full filing history, deal timelines, and sponsor details for EUCR can sign up for complete data access at SpacDesk.